M32.14

End-stage renal disease in systemic lupus erythematosus

End-stage renal disease (ESRD) in systemic lupus erythematosus (SLE) refers to the irreversible and severe deterioration of kidney function as a complication of lupus nephritis (LN), necessitating renal replacement therapy (dialysis or kidney transplantation). SLE is a chronic autoimmune disease characterized by the production of autoantibodies that can attack various organs and tissues, including the kidneys. When the kidneys are affected, it is known as lupus nephritis, which is one of the most severe manifestations of SLE and a major cause of morbidity and mortality. ## Pathophysiology Lupus nephritis arises from the deposition of immune complexes (composed of autoantibodies like anti-dsDNA and nuclear antigens) within the glomeruli and other renal structures. This deposition triggers an inflammatory cascade, involving complement activation and recruitment of inflammatory cells, leading to glomerular damage. Over time, chronic inflammation, proliferation of intrinsic renal cells, and subsequent sclerosis (scarring) replace healthy kidney tissue, impairing filtration and reabsorptive functions. The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification system for lupus nephritis categorizes renal biopsy findings into six classes (I-VI). Progression to ESRD is most commonly associated with severe forms such as Class IV (diffuse proliferative lupus nephritis) and, ultimately, Class VI (advanced sclerosing lupus nephritis), where more than 90% of glomeruli are globally sclerosed. Persistent proteinuria, uncontrolled hypertension, and chronic tubulointerstitial inflammation also contribute significantly to the progressive decline in renal function. Genetic predispositions, certain racial/ethnic backgrounds, and environmental factors can influence the severity and progression of LN. ## Clinical Presentation The clinical presentation of lupus nephritis can range from asymptomatic proteinuria and microscopic hematuria to full-blown nephrotic syndrome (severe proteinuria, hypoalbuminemia, edema, hyperlipidemia) or rapidly progressive glomerulonephritis. As kidney function deteriorates towards ESRD, patients develop symptoms of uremia. These include profound fatigue, nausea, vomiting, anorexia, pruritus (itching), muscle cramps, and cognitive impairment (uremic encephalopathy). Fluid overload can lead to peripheral edema, pulmonary edema (shortness of breath), and hypertension. Other complications like anemia of chronic disease, metabolic bone disease (renal osteodystrophy), and electrolyte imbalances (hyperkalemia, hyperphosphatemia) become prominent. Systemic symptoms of SLE, such as joint pain, skin rashes, and serositis, may still be present or may have attenuated as kidney disease progresses. ## Diagnostic Criteria The diagnosis of ESRD due to SLE requires a confirmed diagnosis of SLE (based on established criteria such as the ACR or EULAR/ACR classification criteria) and evidence of chronic, irreversible kidney failure. Initially, lupus nephritis is diagnosed or suspected based on abnormal urinalysis (proteinuria >0.5 g/24h or cellular casts) and/or rising serum creatinine. A renal biopsy is paramount for confirming lupus nephritis, classifying its histological type (ISN/RPS classification), assessing activity and chronicity indices, and guiding treatment. ESRD is defined by a glomerular filtration rate (GFR) less than 15 mL/min/1.73 m² or the need for renal replacement therapy (dialysis or kidney transplantation). Imaging studies such as renal ultrasound may show small, echogenic kidneys consistent with chronic kidney disease. ## Standard of Care The management of ESRD in SLE shifts from immunosuppressive therapy aimed at preserving kidney function (which is crucial in earlier stages of lupus nephritis using agents like cyclophosphamide, mycophenolate mofetil, or calcineurin inhibitors) to renal replacement therapy. This includes either hemodialysis, peritoneal dialysis, or kidney transplantation. Dialysis manages uremic symptoms and fluid/electrolyte imbalances, while kidney transplantation offers the best long-term outcome and quality of life. Patients undergoing transplantation still require immunosuppression to prevent transplant rejection and may also need ongoing SLE-specific therapy to prevent recurrence of lupus nephritis in the transplanted kidney or flares in other organ systems. Supportive care is critical, including rigorous blood pressure control (often with ACE inhibitors or ARBs, though these may be limited in advanced ESRD), dietary modifications, anemia management (erythropoiesis-stimulating agents, iron), bone mineral disorder management, and cardiovascular risk reduction. A multidisciplinary approach involving nephrologists, rheumatologists, dietitians, and social workers is essential for comprehensive patient care.

Clinical Symptoms

  • Proteinuria (foamy urine)
  • Hematuria (blood in urine)
  • Edema (swelling of face, hands, feet, ankles)
  • Hypertension (high blood pressure)
  • Fatigue
  • Nausea and vomiting
  • Anorexia (loss of appetite)
  • Pruritus (itching)
  • Muscle cramps or weakness
  • Shortness of breath (dyspnea), especially with exertion or fluid overload
  • Reduced urine output (oliguria or anuria in late stages)
  • Cognitive impairment (difficulty concentrating, memory problems)
  • Peripheral neuropathy (numbness, tingling in extremities)
  • Pericarditis or pleuritis (chest pain, shortness of breath from inflammation of heart/lung lining)
  • Anemia
  • Bone pain (due to renal osteodystrophy)
  • Weight loss
  • Skin rashes (e.g., malar rash, discoid rash - may persist from SLE)
  • Joint pain (arthralgia - may persist from SLE)

Common Causes

  • Systemic Lupus Erythematosus (SLE) as the primary autoimmune disease
  • Autoantibody production (e.g., anti-dsDNA, ANA, anti-Sm) leading to immune complex formation
  • Immune complex deposition in renal glomeruli and tubules
  • Chronic inflammation and complement activation in renal tissue
  • Progressive glomerular damage and sclerosis (scarring) of kidney tissue
  • Specific histological classes of lupus nephritis (e.g., ISN/RPS Class IV - diffuse proliferative, and Class VI - advanced sclerosing)
  • Persistent or relapsing lupus nephritis flares
  • Non-adherence to immunosuppressive therapy for lupus nephritis
  • Poorly controlled hypertension
  • High baseline proteinuria during lupus nephritis
  • Genetic predispositions
  • Certain racial/ethnic groups (e.g., African Americans, Hispanics, Asians) having higher risk of severe LN and progression to ESRD
  • Delayed diagnosis or inadequate treatment of lupus nephritis
  • Chronic tubulointerstitial disease contributing to renal fibrosis
  • Secondary factors like obesity and smoking potentially exacerbating kidney damage

Documentation & Coding Tips

Explicitly Document the Causal Relationship

Example: The patient is a 45-year-old female with Systemic Lupus Erythematosus (SLE) and concomitant End-Stage Renal Disease (ESRD) due to lupus nephritis. The patient is currently on hemodialysis three times per week via a right-arm arteriovenous fistula. The ESRD is a direct manifestation of her SLE activity over the last decade.

Billing Focus: Documentation must specify the causal link using terms like due to or manifestation of to support M32.14 as the primary diagnosis.

Include Dialysis Status for Completeness

Example: Patient with M32.14 presents for evaluation of anemia. Documented ESRD due to SLE, currently dialysis-dependent (Z99.2). Arteriovenous fistula in left forearm is patent with audible thrill and palpable bruit.

Billing Focus: Adding Z99.2 (Dependence on renal dialysis) is essential for billing dialysis-related services and outpatient facility claims.

Document Associated Manifestations and Comorbidities

Example: Systemic lupus erythematosus with end-stage renal disease (M32.14). Also noting secondary hyperparathyroidism of renal origin and anemia of chronic kidney disease, currently managed with Aranesp and phosphate binders.

Billing Focus: Specificity in documenting secondary conditions like renal osteodystrophy or anemia of CKD allows for more accurate coding of the entire clinical picture.

Distinguish Between Lupus Nephritis and ESRD

Example: Patient has transitioned from Stage 4 Lupus Nephritis to ESRD (M32.14). The patient is no longer responding to immunosuppressive therapy for active nephritis and is now being prioritized for renal transplant list evaluation.

Billing Focus: Avoid using M32.11 (Lupus nephritis) once the patient has reached ESRD; M32.14 is the more specific and appropriate code for this stage.

Specify the Type and Frequency of Encounters

Example: Established patient with M32.14 seen for 45 minutes of face-to-face time. High medical decision making involved in managing SLE flares while balancing dialysis restrictions and electrolyte imbalances.

Billing Focus: Time-based documentation must meet the 2026 thresholds for 99215 (40-54 minutes) or 99214 (30-39 minutes) for established patients.

Relevant CPT Codes

Related Diagnoses

Hierarchy